CME: Emerging perspectives in the diagnosis and management of hypertrophic cardiomyopathy

Overview
Left ventricular hypertrophy has been recognized as an entity of hypertrophy cardiomyopathy (HCM) for hundreds of years. Many etiologies have been discovered since the beginning of the description of HCM. It is important to identify the etiology in a patient with HCM as it drives the treatment plan for these patients.
This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
Program Highlights
This educational program consists of three presentations on hypertrophic cardiomyopathy (HCM).
HCM: Understanding the condition - Perry Elliott, MD – London, UK
- Perry Elliott gives a brief overview of the history, diagnosis, imaging and genetics of hypertrophic cardiomyopathy (HCM).
Diagnosing HCM: What a cardiologist needs to know - Aleš Linhart, MD, PhD – Prague, Czech Republic
- “Hypertrophic cardiomyopathy is an underdiagnosed condition”, says Aleš Linhart. He explains what the ‘cardiomyopathy mindset’ entails and reviews 5 steps of a patient’s trajectory in the cardiology practice.
Novel approaches in managing patients with HCM – Iacopo Olivotto, MD – Florence, Italy
- Iacopo Olivotto reviews the development of cardiac myosin inhibitors for the treatment of hypertrophic cardiomyopathy. Where are we now and what does the future hold?
Instructions
- Watch the three lectures and answer the pre- and post-test questions
- Fill in the evaluation questions
- Download CME Certificate
For questions regarding this activity, please contact us at info@pace-cme.org.
Learning Objectives
- Recall the definition and characteristics of HCM in adults
- Describe the process of differential diagnosis
- Discuss the interpretation of genetic testing in HCM
- Memorize the recommendations for a cardiac myosin inhibitor in the ESC guidelines
- Explain the mechanism of action of cardiac myosin inhibitors
Target Audience
This educational activity is designed for all healthcare professionals with an interest in management of patients with HCM.
Accreditation and Credit Designation Statements
This online course is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit.
Through an agreement between EBAC and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Commercial Support
Funding for this educational program was provided by an unrestricted educational grant from Bristol Myers Squibb.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-cme.
Declarations of interest:
Perry Elliott, MD – London, UK:
- Consultancies/Ad Board: MyoKardia (BMS), Pfizer, Sanofi-Genzyme, DinaQor, Astra Zeneca, Sarepta, Freeline
Aleš Linhart, MD, PhD – Prague, Czech:
No disclosures for this session

Iacopo Olivotto, MD – Florence, Italy:
Research Support: BMS-Myokardia, Cytokinetics, Sanofi Genzyme, Shire Takeda, Amicus, Bayer, Menarini International, Boston Scientific.
Advisory board, invited speaker: BMS-Myokardia, Cytokinetics, Sanofi, Genzyme, Shire Takeda, Amicus, Tenaya, Rocket Pharma.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 07/12/2023
Expiration Date: 07/12/2025

Perry Elliott, MD

Aleš Linhart, MD, PhD

Iacopo Olivotto, MD

Title

Share on ReachMD